BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...BRAF kinase inhibitor Tafinlar dabrafenib and MAP2K1/2 inhibitor Mekinist trametinib, failed to improve progression-free survival compared with the Tafinlar/Mekinist...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

...stabilizes Raf family kinases in their inactive conformations; in contrast, type I inhibitors like Tafinlar dabrafenib...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

...an anti-PD-1 mAb that is in the Phase III COMBI-i trial in combination with Tafinlar dabrafenib...
BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

...programs that inhibiting BRAF and MEK would be be effective in BRAF-mutant melanoma. GSK’s Tafinlar dabrafenib...
BioCentury | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

...unresectable or metastatic melanoma. The combination was third to market in BRAF-mutant disease, trailing Tafinlar dabrafenib/Mekinist...
BioCentury | Jul 25, 2018
Distillery Therapeutics

Cancer

...a patient-derived xenograft (PDX) mouse model of melanoma, the combination of the RXR inhibitor, Tafinlar dabrafenib...
...tumors in three of eight treated animals and increased progression-free survival (PFS) compared with the Tafinlar...
...trametinib (Generic), Mekinist (Other), 1120212 (Other) Tafinlar (Brand), GSK2118436 (Compound #), 2118436 (Compound #), dabrafenib (Generic), Tafinlar...
BioCentury | Jul 13, 2018
Preclinical News

RXR a potential minimal residual disease target in melanoma

...alone or in combination with MEK inhibition, and treated the mice with BRAF inhibitor Tafinlar dabrafenib...
...patient-derived xenograft melanoma mouse model with Tafinlar and Mekinist plus a tool RXR inhibitor or Tafinlar...
BioCentury | Jun 30, 2018
Product Development

Defining access potential - before it’s too late

...medicines for melanoma that does not appear to be a major improvement over Novartis AG’s Tafinlar/Mekinist...
...PFS) of 14.9 months vs. 7.3 months for the BRAF inhibitor Zelboraf vemurafenib. The competitor Tafinlar/Mekinist...
BioCentury | Jun 12, 2018
Emerging Company Profile

A Cancer Target Revolution

...monotherapy in the U.S. to treat BRAF V600 mutation-positive melanoma and in combination with Tafinlar dabrafenib...
BioCentury | Jun 8, 2018
Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

...bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist...
...two cases of stable disease in three patients. In seven patients who received bemcentinib plus Tafinlar/Mekinist...
...trametinib (Generic), Mekinist (Other), 1120212 (Other) Tafinlar (Brand), GSK2118436 (Compound #), 2118436 (Compound #), dabrafenib (Generic), Tafinlar...
Items per page:
1 - 10 of 160